BUFFALO, N.Y., May 7, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company will hold its 2012 annual stockholders meeting at 10:00 a.m. ET on June 13, 2012 at the Company's headquarters located at 73 High Street, Buffalo, NY, 14203 for stockholders of record as of April 19, 2012. The Company will distribute proxy materials to all eligible stockholders.

A Cleveland BioLabs investor day will take place following the stockholders meeting at 1:00 p.m. ET on June 13, at the Company's headquarters in Buffalo, NY. RSVPs are required for investor day attendees. Interested parties may contact Rachel Levine, Director, Investor Relations and Communications at rlevine@cbiolabs.com or 646-284-9439 for more information or to RSVP.

Live and archived webcasts of the stockholders meeting and investor day will be available on the investor page of the Cleveland BioLabs web site atwww.cbiolabs.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a direct acting anticancer agent. The Company has two subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute of Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website athttp://www.cbiolabs.com.

The Cleveland BioLabs, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11668

Rachel Levine, Director Investor Relations & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com